ADCC Activity of Various Effector Cells in Myeloma Patients
| Source of Effector Cells . | CD16+ Cells (%) . | ADCC Activity (%) . | |
|---|---|---|---|
| Medium . | IL-2– Stimulated . | ||
| PBMCs | 12 ± 6 | 30 ± 9 | 45 ± 9* |
| BMMCs | 7 ± 5 | 17 ± 20 | 31 ± 12 |
| PBSC collections | 29 ± 6† | 21 ± 9 | 36 ± 10* |
| Source of Effector Cells . | CD16+ Cells (%) . | ADCC Activity (%) . | |
|---|---|---|---|
| Medium . | IL-2– Stimulated . | ||
| PBMCs | 12 ± 6 | 30 ± 9 | 45 ± 9* |
| BMMCs | 7 ± 5 | 17 ± 20 | 31 ± 12 |
| PBSC collections | 29 ± 6† | 21 ± 9 | 36 ± 10* |
PBMCs and BMMCs were obtained from five myeloma patients before PBSC harvest. Effector cells were cultured alone or with IL-2 (500 U/mL) for 3 days, then tested for ADCC activity against RPMI 8226 cells at an E/T ratio of 50 in the presence of humanized anti-HM1.24 MoAb (1 μg/mL). Results are expressed as the mean ± SD.
P < .05, compared with the data of nonactivated effector cells.
P < .005, compared with the percentage of PBMCs.